Longitudinal Decline of Alanine Aminotransferase in Parkinson’s Disease and Its Association with Disease Duration

Imagine your body as a bustling, high-tech city. In this city, the liver is the central recycling plant and chemical processing hub. It's responsible for filtering out toxins, managing fuel (like sugar and fat), and keeping the whole system running smoothly. One of the workers in this plant is an enzyme called Alanine Aminotransferase, or ALT for short. Think of ALT as a specific type of traffic officer that helps manage the flow of chemicals. Usually, we only notice these officers when something goes wrong and they spill out into the bloodstream, signaling a problem. But scientists have started wondering: what if the number of these officers dropping in the blood could actually tell us something about a different part of the city entirely—the brain?

Parkinson's disease is a condition where the brain's "motor control center" slowly loses its ability to send smooth signals to the body, leading to shaking, stiffness, and trouble moving. For years, doctors have been hunting for a simple, non-invasive way to spot this disease early, perhaps even before the shaking starts. They've looked at everything from brain scans to spinal fluid, but those are like sending a drone into a locked building—hard to do and uncomfortable for the patient. Blood tests, on the other hand, are like checking the city's main water supply: easy, routine, and done all the time. This study asks a simple, curious question: If we track the "traffic officers" (ALT) and a few other blood markers over several years, do they change in a way that matches the story of Parkinson's disease?

The Great Liver Detective Story

In this study, a team of researchers from Tel Aviv decided to play detective with blood samples. They followed two groups of people over a median of four years. The first group was made up of 175 people already diagnosed with Parkinson's disease. The second group was a "control" crew of 345 people who looked healthy and didn't have the disease. To make the investigation extra sharp, they looked at different genetic "flavors" of Parkinson's (some caused by a gene called LRRK2, others by GBA1, and some with no known genetic cause) to see if the blood markers behaved differently for each type.

They focused on three main suspects in the blood:

1. ALT (Alanine Aminotransferase): The liver traffic officer.
2. AST (Aspartate Aminotransferase): A similar officer that works in the liver but also hangs out in muscles and the heart.
3. NLR (Neutrophil-to-Lymphocyte Ratio): A score that compares two types of immune system soldiers (neutrophils and lymphocytes) to see if the body is in a state of low-level alarm.

The Plot Twist: The Officers Are Disappearing

Here is what the researchers found, and it's a bit of a plot twist.

When they looked at the blood samples at the start of the study, the people with Parkinson's already had lower levels of ALT compared to the healthy group. But the real story happened over time. As the years rolled on, the ALT levels in the Parkinson's group didn't just stay low; they continued to drop. It was like watching a slow leak in a tire. In contrast, the healthy people's ALT levels actually crept up slightly over the same four years.

The researchers calculated that in the Parkinson's group, ALT dropped by a median of 2 U/L between the first and second check-ups. In the healthy group, it went up by a median of 1 U/L. While those numbers sound small, the pattern was clear and statistically significant.

But here is the big question: Is this drop because of the Parkinson's disease itself, or is it just a side effect of the medicine people take to treat it? Parkinson's patients often take a lot of medication (specifically levodopa) to help their brains. The researchers were very careful to check this. They found that while the medication did play a part (accounting for about 29.4% of the drop), it wasn't the whole story. Even when they looked at the small group of patients who weren't taking any Parkinson's medication yet, or when they did the math to remove the medication's influence, the ALT levels were still lower and still dropping as the disease lasted longer.

This suggests that the falling ALT levels are likely a reflection of the disease's own biology—a change happening inside the body's systems as Parkinson's progresses—rather than just a chemical reaction to the pills.

The Other Suspects: A Mixed Bag

What about the other two suspects?

• AST: This enzyme didn't show a consistent pattern. It didn't drop or rise in a way that clearly separated the Parkinson's group from the healthy group. The researchers concluded that AST is probably too "busy" working in other parts of the body (like muscles) to be a reliable signal for Parkinson's.
• NLR (The Immune Ratio): In some quick snapshots, the immune ratio looked higher in Parkinson's patients, which fits with the idea that the disease involves some inflammation. However, when the researchers tracked this over the four years, the pattern wasn't stable or consistent enough to be a reliable marker. It seemed to change too much based on other factors to be a solid "Parkinson's detector."

The Genetic Clue

The team also wondered if the "flavor" of Parkinson's mattered. Maybe the LRRK2 type had different liver markers than the GBA1 type? Surprisingly, the answer was no. The ALT levels dropped in the same way regardless of which genetic mutation the person carried. The liver's "traffic officers" seemed to be reacting to the general presence of the disease, not the specific genetic cause.

What Does This Mean?

So, what's the takeaway for our city? The study suggests that ALT is a "candidate biomarker." That's a fancy way of saying it's a promising clue, but not a smoking gun yet. The fact that ALT drops as the disease gets older and lasts longer suggests it might be tied to how the body handles metabolism and toxins in a way that goes hand-in-hand with Parkinson's.

However, the authors are careful not to get too excited. They point out that the changes are small. You can't look at a single blood test and say, "Aha! You have Parkinson's!" because the effect size is too small to be used as a standalone diagnostic tool right now. Also, they noted that they didn't measure Vitamin B6 levels, which are needed for ALT to work, and since Parkinson's medications can lower Vitamin B6, that's a missing piece of the puzzle.

In the end, this research adds a new, interesting piece to the puzzle. It tells us that the liver and the brain might be talking to each other in a way we didn't fully appreciate before. While ALT isn't the magic key to diagnosing Parkinson's today, it's a hint that the disease might be a whole-body event, not just a brain problem. And in the world of science, even a small, consistent clue can lead to a bigger discovery down the road.